STOCK TITAN

Cosmos Health Inc. - COSM STOCK NEWS

Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.

Overview of Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ:COSM) is a diversified, vertically integrated global healthcare company specializing in the development, manufacturing, and distribution of nutraceuticals, pharmaceuticals, and over-the-counter (OTC) medicines. Established in 2009 and headquartered in Chicago, Illinois, Cosmos Health operates across multiple business segments, including wholesale drug distribution, proprietary product lines, contract manufacturing, and telehealth services. The company’s vertically integrated model enables it to control every stage of its value chain, from research and development (R&D) to production and global distribution, ensuring high-quality standards and operational efficiency.

Core Business Segments

Nutraceuticals and Proprietary Brands

Cosmos Health is a prominent player in the nutraceuticals market, offering a range of premium products under its proprietary brands, such as Sky Premium Life® and Mediterranation®. These brands are designed to meet the growing demand for health and wellness solutions, with products ranging from dietary supplements to specialized formulations addressing various health needs. The company’s R&D team focuses on creating innovative nutraceuticals, leveraging natural ingredients like Kakadu Plum and advanced formulations such as ZenBlend for relaxation and Skinovate for anti-aging.

Pharmaceuticals and Manufacturing

In the pharmaceutical sector, Cosmos Health provides a comprehensive portfolio of branded generics, OTC medicines, and proprietary complex generics. Its subsidiary, Cana Laboratories S.A., operates under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA). This facility manufactures a wide array of products, including pharmaceuticals, food supplements, cosmetics, and medical devices, ensuring compliance with stringent international quality standards. The company also engages in contract manufacturing for specialty pharmaceutical firms, producing high-demand products such as Baclofen solutions and vitamin B-complex tablets.

Wholesale Distribution

The wholesale segment is a significant revenue driver for Cosmos Health, supplying pharmaceuticals and parapharmaceuticals to retail pharmacies and healthcare providers. With a robust distribution network spanning Europe, Asia, and North America, the company has established itself as a reliable partner for wholesale drug distributors and retail healthcare providers.

Telehealth and Digital Healthcare

Cosmos Health has embraced digital transformation through its telehealth platform, ZipDoctor, Inc. This service offers remote healthcare solutions, catering to the increasing demand for accessible and efficient medical consultations. The integration of telehealth into its business model underscores the company’s commitment to innovation and patient-centric care.

Research and Development (R&D) Initiatives

R&D is a cornerstone of Cosmos Health’s strategy, with a focus on addressing critical health challenges such as obesity, diabetes, cancer, and autoimmune disorders. The company leverages artificial intelligence (AI) through its Cloudscreen platform for drug repurposing, accelerating the development of novel treatments. Recent advancements include patents for anticancer drugs targeting prostate, ovarian, and colorectal cancers, as well as innovative solutions for multiple sclerosis and allergic inflammation.

Global Expansion and Strategic Partnerships

Cosmos Health continues to expand its global footprint through strategic partnerships and distribution agreements. Notable collaborations include exclusive rights to distribute Virax Biolabs’ diagnostic kits in Europe and the Gulf Cooperation Council (GCC) countries. The company’s products are available in leading international retail chains and e-commerce platforms, further solidifying its market presence.

Competitive Positioning

In a competitive healthcare landscape, Cosmos Health differentiates itself through its vertically integrated operations, innovative R&D, and a diverse product portfolio. Its focus on high-margin proprietary brands and strategic geographic expansion positions the company as a growing contender in the global healthcare market.

Conclusion

With a commitment to innovation, quality, and global reach, Cosmos Health Inc. is poised to address some of the most pressing challenges in healthcare. Its diversified business model, coupled with cutting-edge R&D initiatives, ensures a sustainable growth trajectory in the nutraceutical, pharmaceutical, and telehealth sectors.

Rhea-AI Summary

Cosmos Health's subsidiary CosmoFarm reported record revenue of $43 million for the first ten months of 2024, marking an 8.62% increase from the previous year, accompanied by a 21% rise in gross profit. The growth is attributed to investments in advanced robotic systems for automated operations, expanded sales and marketing initiatives, and strategic acquisitions of distribution networks. CosmoFarm, operating from a 29,000-square-foot facility in Athens, serves over 1,500 pharmacies and is projected to exceed $52 million in annualized revenue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
none
-
Rhea-AI Summary

Cosmos Health Inc. (NASDAQ:COSM) has reported a significant 160% increase in sales of its proprietary brands on Amazon UK for the year-to-date 2024. Sales have risen to $596,000 from $230,000 during the same period in 2023. The company's CEO, Greg Siokas, expressed satisfaction with the strong reception of their brands in the UK market and anticipates continued growth momentum. He also highlighted that the company's brands benefit from strong profit margins, which is expected to contribute to solid profitability as they expand their revenue base.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
none
-
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has received initial purchase orders exceeding $500,000 for its C-Scrub Wash Chlorhexidine 4% in the UK market for the period from July to September 2024. The company is securing additional orders for October 2024 and beyond, anticipating substantial profitability due to high profit margins associated with C-Scrub. Cosmos Health's sales strategy targets diverse customers, including hospitals, wholesalers, and direct-to-consumer channels through online platforms like Amazon, TikTok, and eBay.

CEO Greg Siokas expressed satisfaction with the progress in bringing C-Scrub to the UK market, noting strong demand and anticipating accelerated order pace in the coming months. The company's diversified approach aims to capitalize on multiple distribution channels to maximize market penetration and sales potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.18%
Tags
none
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has entered an exclusive agreement with Virax Biolabs to distribute mpox virus real-time PCR detection kits across India, a market with over 1.4 billion people. This expansion follows a recent second reported case of mpox in India on September 18, 2024. The agreement positions Cosmos Health to support India's efforts in identifying and managing mpox cases, contributing to public health initiatives.

This move comes after the WHO declared a global public health emergency on August 14, 2024, due to rising mpox cases in Africa and its spread to Europe and Asia. The agreement extends Cosmos Health's partnership with Virax beyond Europe, following a recent exclusive distribution agreement for the Gulf region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.18%
Tags
none
-
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has entered the development phase for CCDL24, an innovative treatment for gastrointestinal (GI) disorders. The product utilizes advanced biopolymeric grids from natural ingredients to encapsulate bioactive molecules, enhancing drug efficacy at targeted sites. Current efforts focus on improving physicochemical properties and evaluating gut microflora impact through in vitro studies and simulations.

The global gastrointestinal therapeutics market, valued at $37.6 billion in 2022, is projected to grow at a 3.3% CAGR from 2023 to 2030. This growth is driven by the increasing prevalence of GI disorders and rising demand for effective treatments. CCDL24 builds on the success of CCX0722, leveraging biocompatible hydrogels from natural sources to create biopolymeric matrices for gastrointestinal health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has released its updated guidance for 2024-2027, projecting significant growth across key financial metrics. The company anticipates revenue to increase by 163% from $59.35 million in 2024 to $155.80 million in 2027, with gross profit expected to rise by 653% from $6.25 million to $47.06 million over the same period. Net income is projected to grow by 402%, reaching $20.44 million in 2027 from a loss of $6.76 million in 2024.

The company's strategy focuses on expanding high-margin segments, including the global growth of proprietary brands like Sky Premium Life, C-sept, and C-scrub. Cosmos Health also plans to optimize its Contract Manufacturing Organization operations and progress with its CCX obesity pill. The guidance reflects a shift towards profitability, with positive operating cash flow expected from 2025 onwards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
Rhea-AI Summary

Taglich Brothers has published an updated coverage report on Cosmos Health (NASDAQ:COSM), maintaining a Speculative Buy rating with a $4 price target, nearly 300% above the current share price. The report highlights significant growth expectations as Cosmos transitions into a vertically integrated global health organization. Key drivers include increased contract manufacturing at Cana Laboratories and expanded distribution agreements for nutraceutical and disinfectant brands in Europe and the Middle East.

Taglich forecasts FY 2024 revenue at $56.3 million, with a 22.6% increase to $69.0 million in FY 2025, alongside a projected operating profit of $20,000 and cash earnings of $1.6 million. The report suggests that Cosmos Health's valuation should improve with revenue growth and transition to profitability, as its current price-to-sales multiple (0.3X) lags behind the 2.4X sector average.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.43%
Tags
none
-
Rhea-AI Summary

Virax Biolabs Group (NASDAQ: VRAX) has extended its exclusive distribution agreement with Cosmos Health Inc. (Nasdaq: COSM) to market Mpox Virus Real-Time PCR Detection Kits in Gulf Cooperation Council (GCC) countries. This expansion follows their existing agreement for Greece, Cyprus, and non-exclusive distribution in Europe. The CE-marked and MHRA-authorized kits boast a 96.7% sensitivity and 93.72% specificity, delivering results in under 70 minutes.

The agreement allows Cosmos to import, sell, and distribute Virax-branded Mpox virus Nucleic Acid Detection Kits in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Both companies express excitement about the partnership, with Virax CEO James Foster highlighting the expanded geographic reach and Cosmos CEO Greg Siokas noting the continued strong demand for Mpox virus detection kits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
none
-
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has expanded its exclusive distribution agreement with Virax Biolabs (NASDAQ:VRAX) to commercialize mpox virus real-time PCR detection kits in Gulf Cooperation Council (GCC) countries. This extension builds upon their previous agreement for Greece, Cyprus, and non-exclusive distribution across Europe. The kits, CE-marked and MHRA-authorized, offer 96.7% sensitivity and 93.72% specificity, delivering results in under 70 minutes.

The agreement comes in response to the WHO's declaration of mpox as a public health emergency in August 2024, with cases spreading beyond Africa to Europe and Asia. Cosmos Health aims to support governments and public health authorities in Europe and the Gulf by enhancing preparedness and ensuring rapid detection of mpox cases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
none
Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has regained full compliance with Nasdaq listing requirements. The company addressed two key issues:

1. Filing Compliance: Cosmos filed its 2023 Annual Report (Form 10-K) and Q1 2024 financial results (Form 10-Q), resolving concerns raised in Nasdaq's notification letters from April and May 2024.

2. Minimum Bid Price Rule: The company met this requirement earlier in July 2024.

CEO Greg Siokas expressed satisfaction with the company's return to full compliance across all Nasdaq listing requirements. This development marks a positive turn for Cosmos Health, a diversified healthcare group involved in R&D, pharmaceutical and nutraceutical brands, healthcare product distribution, and telehealth services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
none

FAQ

What is the current stock price of Cosmos Health (COSM)?

The current stock price of Cosmos Health (COSM) is $0.451 as of March 28, 2025.

What is the market cap of Cosmos Health (COSM)?

The market cap of Cosmos Health (COSM) is approximately 11.2M.

What does Cosmos Health Inc. specialize in?

Cosmos Health Inc. specializes in nutraceuticals, pharmaceuticals, and telehealth, offering proprietary brands and innovative healthcare solutions.

How does Cosmos Health generate revenue?

The company generates revenue through wholesale drug distribution, proprietary product sales, contract manufacturing, and telehealth services.

What are some of Cosmos Health’s proprietary brands?

Key proprietary brands include Sky Premium Life® and Mediterranation®, focusing on high-quality nutraceuticals and wellness products.

What is Cosmos Health’s approach to R&D?

The company leverages AI-driven drug repurposing and innovative research to develop treatments for conditions like cancer, obesity, and autoimmune disorders.

Where does Cosmos Health operate?

Cosmos Health has a global presence, with operations in Europe, Asia, and North America, and distribution centers in Greece and the UK.

What makes Cosmos Health unique in the healthcare industry?

Its vertically integrated model, innovative R&D initiatives, and focus on high-margin proprietary brands set it apart in the competitive healthcare market.

What is the role of AI in Cosmos Health’s operations?

Cosmos Health uses AI through its Cloudscreen platform to accelerate drug repurposing and enhance the development of novel treatments.

What are some recent advancements by Cosmos Health?

Recent advancements include patents for anticancer drugs, a weight management solution, and expansion into telehealth through ZipDoctor.
Cosmos Health Inc.

Nasdaq:COSM

COSM Rankings

COSM Stock Data

11.15M
16.36M
29.66%
6.97%
3.46%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
THESSALONIKI